Skip to main content
Premium Trial:

Request an Annual Quote

The R&D Version of Musical Chairs

Martin Mackay is leaving his spot as the head of research and development at Pfizer to join AstraZeneca, where he will serve in the same capacity, reports Fierce Biotech. The Wall Street Journal's Health Blog adds that Mackay shared that spot at Pfizer with Mikael Dolsten, who was head of R&D at Wyeth, and Dolsten will now be the sole person leading that section at Pfizer. The R&D position at AstraZeneca that Mackay is taking is new, and he will have the drug discovery and drug development section reporting to him. "Martin's appointment to this new role will provide a single point of senior accountability as we continue to make the changes necessary to improve the productivity and efficiency of our research and development organization," says AstraZeneca CEO's David Brennan in a statement.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.